Medical Oncology

, 31:75 | Cite as

Genetic polymorphism of metallothionein 2A and risk of laryngeal cancer in a Polish population

  • Katarzyna StarskaEmail author
  • Anna Krześlak
  • Ewa Forma
  • Jurek Olszewski
  • Iwona Lewy-Trenda
  • Ewa Osuch-Wójcikiewicz
  • Magdalena Bryś
Original Paper


Metallothioneins are intracellular regulators of many biological mechanisms including differentiation, proliferation, angiogenesis and invasion, which are crucial processes in carcinogenesis. This study examines the association between three single-nucleotide polymorphisms at loci −5 A/G (rs28366003) and −209 A/G (rs1610216) in the core promoter region and at locus +838 C/G (rs10636) in 3′UTR region of the metallothionein 2A (MT2A) gene with squamous cell laryngeal cancer (SCLC) risk, as well as with tumor invasiveness according to tumor front grading (TFG). Genotyping was performed using the polymerase chain reaction–restriction fragment length polymorphism technique in 323 genetically unrelated individuals with SCLC and 418 randomly selected healthy volunteers. Only one SNP (rs28366003) was significantly related to laryngeal cancer in the study population. Compared with homozygous common allele carriers, heterozygous and homozygous for the G variant had significantly increased risk of SCLC [adjusted odds ratio (OR) = 2.90, 95 % confidence interval (CI) 1.53–5.21, p dominant < 0.001]. The A/G allele carriers at rs28366003 MT2A were at higher risk of SCLC development (OR = 2.63, 95 % CI 1.41–2.85, p < 0.001]. There was a significant association between the rs28366003 and stage and TFG classification. Most carriers of minor allele had a higher stage (OR = 2.76, 95 % CI 1.11–7.52, p = 0.03), increased cancer aggressiveness, as defined by a higher total TFG score (>18 points) (OR = 3.76, 95 % CI 1.15–12.56, p = 0.03) and diffuse tumor growth (OR = 5.86, 95 % Cl 0.72–44.79, p = 0.08). The results of this study raise a possibility that a genetic variation of MT2A may be implicated in the etiology of laryngeal cancer in a Polish population.


Metallothionein 2A (MT2A) Single-nucleotide polymorphism (SNP) Tumor front grading (TFG) Laryngeal cancer 



This work was supported, in part, by grant from the National Science Council, Poland (N403 043 32/2326) and by the statutory fund of the Department of Cytobiochemistry, University of Łódź, Poland (506/811).

Conflict of interest statement

The authors declare to have no conflict of interests.

Ethical statement

The investigations were performed with the approval of the Bioethical Commission of the Medical University of Łódź and the National Science Council, Poland (approval no. RNN/60/13/KE).


  1. 1.
    Raudenska M, Gumulec J, Podlaha O, Sztalmachova M, Babula P, Eckschlager T, Adam V, Kizek R, Masarik M. Metallothionein polymorphisms in pathological processes. Metallomics. 2014;6(1):55–68.PubMedCrossRefGoogle Scholar
  2. 2.
    Kling P, Modig C, Mujahed H, Khalaf H, von Hofsten J, Olsson PE. Differential regulation of the rainbow trout (Oncorhynchus mykiss) MT-A gene by nuclear factor interleukin-6 and activator protein-1. BMC Mol Biol. 2013;14:28. doi: 10.1186/1471-2199-14-28.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Babula P, Masarik M, Adam V, Eckschlager T, Stiborova M, Trnkova L, Skutkova H, Provaznik I, Hubalek J, Kizek R. Mammalian metallothioneins: properties and functions. Metallomics. 2012;4(8):739–50.PubMedCrossRefGoogle Scholar
  4. 4.
    Mehus AA, Muhonen WW, Garrett SH, Somji S, Sens DA, Shabb JB. Quantitation of human metallothionein isoforms: a family of small, highly conserved cysteine-rich proteins. Mol Cell Proteomics. 2014;13(4):1020–33.PubMedCrossRefGoogle Scholar
  5. 5.
    Juang HH, Chung LC, Sung HC, Feng TH, Lee YH, Chang PL, Tsui KH. Metallothionein 3: an androgen-upregulated gene enhances cell invasion and tumorigenesis of prostate carcinoma cells. Prostate. 2013;73(14):1495–506.PubMedCrossRefGoogle Scholar
  6. 6.
    Pedersen MØ, Larsen A, Stoltenberg M, Penkowa M. The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem. 2009;44:29–64.PubMedCrossRefGoogle Scholar
  7. 7.
    Pan Y, Huang J, Xing R, Yin X, Cui J, Li W, Yu J, Lu Y. Metallothionein 2A inhibits NF-κB pathway activation and predicts clinical outcome segregated with TNM stage in gastric cancer patients following radical resection. J Transl Med. 2013;11:173. doi: 10.1186/1479-5876-11-173.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Gumulec J, Balvan J, Sztalmachova M, Raudenska M, Dvorakova V, Knopfova L, Polanska H, Hudcova K, Ruttkay-Nedecky B, Babula P, Adam V, Kizek R, Stiborova M, Masarik M. Cisplatin-resistant prostate cancer model: differences in antioxidant system, apoptosis and cell cycle. Int J Oncol. 2014;44(3):923–33.PubMedGoogle Scholar
  9. 9.
    Fu J, Lv H, Guan H, Ma X, Ji M, He N, Shi B, Hou P. Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway. BMC Cancer. 2013;13:462. doi: 10.1186/1471-2407-13-462.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Habel N, Hamidouche Z, Girault I, Patiño-García A, Lecanda F, Marie PJ, Fromigué O. Zinc chelation: a metallothionein 2A’s mechanism of action involved in osteosarcoma cell death and chemotherapy resistance. Cell Death Dis. 2013;4:e874. doi: 10.1038/cddis.2013.405.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Kobierzycki C, Pula B, Skiba M, Jablonska K, Latkowski K, Zabel M, Nowak-Markwitz E, Spaczynski M, Kedzia W, Podhorska-Okolow M, Dziegiel P. Comparison of minichromosome maintenance proteins (MCM-3, MCM-7) and metallothioneins (MT-I/II, MT-III) expression in relation to clinicopathological data in ovarian cancer. Anticancer Res. 2013;33(12):5375–83.PubMedGoogle Scholar
  12. 12.
    Forma E, Krześlak A, Wilkosz J, Jozwiak P, Szymczyk A, Rozanski W, Bryś M. Metallothionein 2A genetic polymorphisms and risk of prostate cancer in a polish population. Cancer Genet. 2012;205:432–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Krześlak A, Forma E, Jóźwiak P, Szymczyk A, Smolarz B, Romanowicz-Makowska H, Różański W, Bryś M. Metallothionein 2A genetic polymorphisms and risk of ductal breast cancer. Clin Exp Med. 2014;14(1):107–13.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Krześlak A, Forma E, Chwatko G, Jóźwiak P, Szymczyk A, Wilkosz J, Różański W, Bryś M. Effect of metallothionein 2A gene polymorphism on allele-specific gene expression and metal content in prostate cancer. Toxicol Appl Pharmacol. 2013;268:278–85.PubMedCrossRefGoogle Scholar
  15. 15.
    Kita K, Miura M, Yoshida M, Yamazaki K, Ohkubo T, Imai Y, Naganuma A. Potential effect on cellular response to cadmium of a single-nucleotide A –>G polymorphism in the promoter of the human gene for metallothionein IIA. Hum Genet. 2006;120:553–60.PubMedCrossRefGoogle Scholar
  16. 16.
    Kayaaltı Z, Aliyev V, Söylemezoğlu T. The potential effect of metallothionein 2A–5 A/G single nucleotide polymorphism on blood cadmium, lead, zinc and copper levels. Toxicol Appl Pharmacol. 2011;256:1–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Kayaalti Z, Mergen G, Söylemezoğlu T. Effect of metallothionein core promoter region polymorphism on cadmium, zinc and copper levels in autopsy kidney tissues from a Turkish population. Toxicol Appl Pharmacol. 2010;245:252–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Gumulec J, Raudenska M, Adam V, Kizek R, Masarik M. Metallothionein–immunohistochemical cancer biomarker: a meta-analysis. PLoS One. 2014;9(1):e85346. doi: 10.1371/journalpone0085346.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Brazão-Silva MT, Cardoso SV, de Faria PR, Dias FL, Lima RA, Eisenberg AL, Nascimento MF, Loyola AM. Adenoid cystic carcinoma of the salivary gland: a clinicopathological study of 49 cases and of metallothionein expression with regard to tumour behaviour. Histopathology. 2013;63(6):802–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Theocharis S, Klijanienko J, Giaginis C, Rodriguez J, Jouffroy T, Girod A, Point D, Tsourouflis G, Sastre-Garau X. Metallothionein expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patient survival. Histopathology. 2011;59:514–25.PubMedCrossRefGoogle Scholar
  21. 21.
    Pastuszewski W, Dziegiel P, Krecicki T, Podhorska-Okolow M, Ciesielska U, Gorzynska E, Zabel M. Prognostic significance of metallothionein, p53 protein and Ki-67 antigen expression in laryngeal cancer. Anticancer Res. 2007;27:335–42.PubMedGoogle Scholar
  22. 22.
    Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Starska K, Kulig A, Lukomski M. Tumor front grading in prediction of survival and lymph node metastases in patients with laryngeal carcinoma. Adv Med Sci. 2006;51:200–4.PubMedGoogle Scholar
  24. 24.
    Qiao X, Ma ZY, Shao J, Bao WG, Xu JY, Qiang ZY, Lou JS. Biological evaluation of a cytotoxic 2-substituted benzimidazole copper (II) complex: DNA damage, antiproliferation and apoptotic induction activity in human cervical cancer cells. Biometals. 2014;27:155–72.PubMedCrossRefGoogle Scholar
  25. 25.
    Tokar EJ, Benbrahim-Tallaa L, Waalkes MP. Metal ions in human cancer development. Met Ions Life Sci. 2011;8:375–401.PubMedGoogle Scholar
  26. 26.
    Thirumoorthy N, Shyam Sunder A, Manisenthil Kumar K, Senthil Kumar M, Ganesh G, Chatterjee M. A review of metallothionein isoforms and their role in pathophysiology. World J Surg Oncol. 2011;9:54. doi: 10.1186/1477-7819-9-54.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Kayaaltı Z, Sahiner L, Durakoğlugil ME, Söylemezoğlu T. Distributions of interleukin-6 (IL-6) promoter and metallothionein 2A (MT2A) core promoter region gene polymorphisms and their associations with aging in Turkish population. Arch Gerontol Geriatr. 2011;53(3):354–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Kayaalti Z, Söylemezoğlu T. The polymorphism of core promoter region on metallothionein 2A-metal binding protein in Turkish population. Mol Biol Rep. 2010;37(1):185–90.PubMedCrossRefGoogle Scholar
  29. 29.
    Seibold P, Hall P, Schoof N, Nevanlinna H, Heikkinen T, Benner A, Liu J, Schmezer P, Popanda O, Flesch-Janys D, Chang-Claude J. Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients-potential differential effects by radiotherapy? Breast. 2013;22(5):817–23.PubMedCrossRefGoogle Scholar
  30. 30.
    Seibold P, Hein R, Schmezer P, Hall P, Liu J, Dahmen N, Flesch-Janys D, Popanda O, Chang-Claude J. Polymorphisms in oxidative stress-related genes and postmenopausal breast cancer risk. Int J Cancer. 2011;129:1467–76.PubMedCrossRefGoogle Scholar
  31. 31.
    McElroy JA, Bryda EC, McKay SD, Schnabel RD, Taylor JF. Genetic variation at a metallothionein 2A promoter single-nucleotide polymorphism in white and black females in Midwestern United States. J Toxicol Environ Health. 2010;73:1283–7.CrossRefGoogle Scholar
  32. 32.
    Kanda M, Nomoto S, Okamura Y, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S, Nakao A. Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int J Oncol. 2009;35(3):477–83.PubMedGoogle Scholar
  33. 33.
    Tekin D, Kayaaltı Z, Söylemezoğlu T. The effects of metallothionein 2A polymorphism on lead metabolism: are pregnant women with a heterozygote genotype for metallothionein 2A polymorphism and their newborns at risk of having higher blood lead levels? Int Arch Occup Environ Health. 2012;85(6):631–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Gansukh T, Donizy P, Halon A, Lage H, Surowiak P. In vitro analysis of the relationships between metallothionein expression and cisplatin sensitivity of non-small cellular lung cancer cells. Anticancer Res. 2013;33:5255–60.PubMedGoogle Scholar
  35. 35.
    Dutsch-Wicherek M, Popiela TJ, Klimek M, Rudnicka-Sosin L, Wicherek L, Oudinet JP, Skladzien J, Tomaszewska R. Metallothionein stroma reaction in tumor adjacent healthy tissue in head and neck squamous cell carcinoma and breast adenocarcinoma. Neuro Endocrinol Lett. 2005;26:567–74.PubMedGoogle Scholar
  36. 36.
    Liang GY, Lu SX, Xu G, Liu XD, Li J, Zhang DS. Expression of metallothionein and Nrf2 pathway genes in lung cancer and cancer-surrounding tissues. World J Surg Oncol. 2013;11:199. doi: 10.1186/1477-7819-11-199.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Werynska B, Pula B, Muszczynska-Bernhard B, Gomulkiewicz A, Piotrowska A, Prus R, Podhorska-Okolow M, Jankowska R, Dziegiel P. Metallothionein 1F and 2A overexpression predicts poor outcome of non-small cell lung cancer patients. Exp Mol Pathol. 2013;94(1):301–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Katarzyna Starska
    • 1
    Email author
  • Anna Krześlak
    • 2
  • Ewa Forma
    • 2
  • Jurek Olszewski
    • 3
  • Iwona Lewy-Trenda
    • 4
  • Ewa Osuch-Wójcikiewicz
    • 5
  • Magdalena Bryś
    • 2
  1. 1.I Department of Otolaryngology and Laryngological OncologyMedical University of ŁódźLodzPoland
  2. 2.Department of CytobiochemistryUniversity of ŁódźLodzPoland
  3. 3.II Department of Otolaryngology and Laryngological OncologyMedical University of ŁódźLodzPoland
  4. 4.Department of PathologyMedical University of ŁódźLodzPoland
  5. 5.Department of Otolaryngology and Laryngological OncologyMedical University of WarsawWarsawPoland

Personalised recommendations